MDT

96.58

+0.4%↑

137.28

-0.49%↓

VEEV

224.99

+0.5%↑

HQY

92.37

-0.06%↓

PHR.US

16.94

+0.18%↑

MDT

96.58

+0.4%↑

137.28

-0.49%↓

VEEV

224.99

+0.5%↑

HQY

92.37

-0.06%↓

PHR.US

16.94

+0.18%↑

MDT

96.58

+0.4%↑

137.28

-0.49%↓

VEEV

224.99

+0.5%↑

HQY

92.37

-0.06%↓

PHR.US

16.94

+0.18%↑

MDT

96.58

+0.4%↑

137.28

-0.49%↓

VEEV

224.99

+0.5%↑

HQY

92.37

-0.06%↓

PHR.US

16.94

+0.18%↑

MDT

96.58

+0.4%↑

137.28

-0.49%↓

VEEV

224.99

+0.5%↑

HQY

92.37

-0.06%↓

PHR.US

16.94

+0.18%↑

Strona główna・Stock List・Harmony Biosciences Holdings Inc

Harmony Biosciences Holdings Inc

Open

SectorHealthcare

37.46 -1.13

Buy Sell

Overview

Share price change

24h

Current

Min

37.14

Max

37.97

Key metrics
By Trading Economics
Income	11M 51M
Sales	39M 239M
P/E Sector Avg	12.259 78.892
EPS	1.08
Profit margin	21.242
Employees	268
EBITDA	14M 73M

Recommendations
By TipRanks
Recommendations	Buy
12 Months Forecast	+14.35% upside

Market Stats
By TradingEconomics
Market Cap	551M 2.2B
Previous open	38.59
Previous close	37.46

News Sentiment

By Acuity

50%

149 / 374 Ranking in Healthcare

Technical Score

By Trading Central

Confidence

Weak Bullish Evidence

29.8 / N/A Support & Resistance

Harmony Biosciences Holdings Inc Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

29 gru 2025, 22:03 UTC

Major Market Movers

Mining Stocks Slip Near the End of Stellar Year

29 gru 2025, 15:57 UTC

Major Market Movers

Praxis Shares Rise on Ulixacaltamide Breakthrough Designation

29 gru 2025, 23:43 UTC

Market Talk

Nikkei May Decline; Yen in Focus -- Market Talk

29 gru 2025, 23:38 UTC

Acquisitions, Mergers, Takeovers

Manus: Will Continue to Operate From Singapore

29 gru 2025, 23:38 UTC

Acquisitions, Mergers, Takeovers

Manus: Will Continue to Sell, Operate Product Subscription Service Through App, Website

29 gru 2025, 23:37 UTC

Acquisitions, Mergers, Takeovers

Meta Platforms: Will Integrate Manus Service Into Products

29 gru 2025, 23:36 UTC

Acquisitions, Mergers, Takeovers

Meta Platforms: Will Continue to Operate, Sell Manus Service

29 gru 2025, 23:36 UTC

Acquisitions, Mergers, Takeovers

Meta Platforms: Manus's Talent to Join Team to Deliver General-Purpose Agents Across Consumer, Business Products

29 gru 2025, 23:35 UTC

Acquisitions, Mergers, Takeovers

Manus to Join Meta Platforms

29 gru 2025, 21:33 UTC

Acquisitions, Mergers, Takeovers

Origin: Raise Values Kraken at US$8.65 Billion

29 gru 2025, 21:33 UTC

Acquisitions, Mergers, Takeovers

Origin: Octopus Targeting Kraken Separation by Mid 2026

29 gru 2025, 21:31 UTC

Acquisitions, Mergers, Takeovers

BlueScope: Rezoning Will Allow for Range of Commercial, Industrial Development Uses

29 gru 2025, 21:31 UTC

Acquisitions, Mergers, Takeovers

BlueScope Also Says Land Adjacent to Port Kembla Steelworks Rezoned to Special Purpose

29 gru 2025, 21:30 UTC

Acquisitions, Mergers, Takeovers

Origin's Kraken Stake to Remain at 22.7%

29 gru 2025, 21:30 UTC

Acquisitions, Mergers, Takeovers

Origin Will Continue to Hold Its 22.7% Interest in Octopus

29 gru 2025, 21:30 UTC

Acquisitions, Mergers, Takeovers

BlueScope: Guidance Reflects Sustained Strength of Operating Performance in Recent Months

29 gru 2025, 21:30 UTC

Acquisitions, Mergers, Takeovers

Origin: Additional Interest Offsets Dilution From Raise

29 gru 2025, 21:30 UTC

Acquisitions, Mergers, Takeovers

BlueScope Doesn't Expect Material Impact on 1H Guidance Range

29 gru 2025, 21:29 UTC

Acquisitions, Mergers, Takeovers

Origin Waiving Australia Exclusivity to Kraken in Exchange for Additional 1.5% Equity Interest

29 gru 2025, 21:29 UTC

Acquisitions, Mergers, Takeovers

BlueScope Expects to Complete Property Sale for A$76 Million Consideration

29 gru 2025, 21:29 UTC

Acquisitions, Mergers, Takeovers

BlueScope Expects to Complete Property Sale in 2H of FY 2026

29 gru 2025, 21:28 UTC

Acquisitions, Mergers, Takeovers

BlueScope: Selling Residentially Zoned Land in West Dapto to Large Homebuilder

29 gru 2025, 21:28 UTC

Acquisitions, Mergers, Takeovers

Origin: Kraken's Raise Paves Way for Separation From Octopus Energy

29 gru 2025, 21:28 UTC

Acquisitions, Mergers, Takeovers

Origin: Kraken to Raise Total US$1 Billion From New, Existing Investors

29 gru 2025, 21:28 UTC

Acquisitions, Mergers, Takeovers

BlueScope Steel Exchanges Contracts for Sale of 33 Hectares of Land in West Dapto

29 gru 2025, 21:27 UTC

Acquisitions, Mergers, Takeovers

Origin Energy to Invest US$140M in Kraken's Standalone Equity Raise

29 gru 2025, 20:22 UTC

Market Talk

Oil Rebounds As Russia-Ukraine War Seen Continuing -- Market Talk

29 gru 2025, 20:14 UTC

Market Talk

U.S. Natural Gas Futures Rise As Front Month Expires -- Market Talk

29 gru 2025, 20:02 UTC

Acquisitions, Mergers, Takeovers

Union Pacific--Norfolk Southern Merger Targets Trucking Market Share -- Barrons.com

29 gru 2025, 17:36 UTC

Market Talk

U.S. Natural Gas Inventories Swing to Deficit Vs. 5-Year Average -- Market Talk

Peer Comparison

Price change

Harmony Biosciences Holdings Inc Forecast

Price Target

By TipRanks

14.35% upside

12 Months Forecast

Average 43.6 USD 14.35%

High 55 USD

Low 32 USD

Based on 6 Wall Street analysts offering 12 month price targets forHarmony Biosciences Holdings Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Buy

6 ratings

Buy

Hold

Sell

Based on 6 analysts giving stock ratings to Harmony Biosciences Holdings Inc - Dist in the past 3 months.

Technical Score

By Trading Central

29.8 / N/ASupport & Resistance

Bullish events outweigh bearish events.

Recent bullish events outweigh bearish events.

All events are bearish.

Sentiment

By Acuity

149 / 374 Ranking in Healthcare

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

About Harmony Biosciences Holdings Inc

Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy. It also offers HBS-102, a melanin-concentrating hormone receptor 1 for MCH neurons. The company was formerly known as Harmony Biosciences II, Inc. and changed its name to Harmony Biosciences Holdings, Inc. in February 2020. Harmony Biosciences Holdings, Inc. was incorporated in 2017 and is headquartered in Plymouth Meeting, Pennsylvania.